FibroBiologics, Inc. (FBLG): Nasdaq/NYSE listing notice — FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance

FibroBiologics, Inc.

Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.
FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.
Trading continues pending the Panel's decision; no assurance of an extension or successful compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

FibroBiologics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(a)(2), 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(a)(2), 5550(b)(2)

Exact text from the filing

February 3, 2026, the Company received formal notice from the Staff that, based upon the Company’s continued non-compliance with the MVLS Rule, the deficiency serves as an additional basis for the delisting of the Company’s securities from Nasdaq (the “Notice”). The Notice indicated that, in addition to the previously-reported bid price deficiency under Listing Rule 5550(a)(2) (the “Bid Price Rule”), the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s plan to regain compliance with the MVLS Rule in their decision regarding the Company’s request for continued listing on The Nasd

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-041187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.